The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. (Q39790449)
Jump to navigation
Jump to search
scientific article published on April 2010
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells. |
scientific article published on April 2010 |
Statements
The dual PI3K/mTOR inhibitor PI-103 promotes immunosuppression, in vivo tumor growth and increases survival of sorafenib-treated melanoma cells (English)
Rosa Gil
Judit Grueso
Anna Pujol
1 reference
1 reference